SCHEMBL13967448

SCHEMBL13967448

O=C(OCc1ccccc1)[C@@H]1C2OC2CN1C(=O)OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGTR2 P50052 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
PSEN1 P49768 1/20 0.44
PSEN2 P49810 1/20 0.44
APH1B Q8WW43 1/20 0.44
NCSTN Q92542 1/20 0.44
APH1A Q96BI3 1/20 0.44
PSENEN Q9NZ42 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
KLK7 P49862 1/20 0.43
KLK5 Q9Y337 1/20 0.43
HTR2C P28335 1/20 0.43
F2 P00734 2/20 0.43
ELANE P08246 2/20 0.43
CTSG P08311 1/20 0.43
PREP P48147 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12480645 1.00 AGTR2 (0.45) AGTR2MEN1KMT2ANPSR1PSEN1
SCHEMBL12478964 1.00 AGTR2 (0.45) AGTR2MEN1KMT2ANPSR1PSEN1
SCHEMBL15541775 1.00 AGTR2 (0.45) AGTR2MEN1KMT2ANPSR1PSEN1
SCHEMBL14762350 1.00 AGTR2 (0.45) AGTR2MEN1KMT2ANPSR1PSEN1
SCHEMBL30485163 1.00 AGTR2 (0.45) AGTR2MEN1KMT2ANPSR1PSEN1
SCHEMBL23485200 1.00 AGTR2 (0.45) AGTR2MEN1KMT2ANPSR1PSEN1
SCHEMBL16520569 1.00 AGTR2 (0.45) AGTR2MEN1KMT2ANPSR1PSEN1
SCHEMBL2230826 0.93 POLB (0.43) AGTR2MEN1KMT2ANPSR1PSEN1
SCHEMBL16648020 0.93 POLB (0.43) AGTR2MEN1KMT2ANPSR1PSEN1
SCHEMBL2226855 0.93 POLB (0.43) AGTR2MEN1KMT2ANPSR1PSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9815819-B2 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2017-11-14 US disclosed
US-9815819-B2 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2017-11-14 US disclosed
EP-2661433-B1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2017-08-16 EP disclosed
EP-2867225-B1 PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS NOVARTIS AG (CH) 2017-08-09 EP disclosed
EP-2867224-B1 PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS NOVARTIS AG (CH) 2017-07-26 EP disclosed
US-9085555-B2 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2015-07-21 US disclosed
US-9085555-B2 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2015-07-21 US disclosed
US-20150191462-A1 PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS NOVARTIS AG (CH) 2015-07-09 US disclosed
US-20150191462-A1 PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS NOVARTIS AG (CH) 2015-07-09 US disclosed
US-20150141455-A1 COMPLEMENT PATHWAY MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2015-05-21 US disclosed
US-20150141455-A1 COMPLEMENT PATHWAY MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2015-05-21 US disclosed
WO-2014002058-A2 COMPLEMENT PATHWAY MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2014-01-03 WO disclosed
WO-2014002052-A1 PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS NOVARTIS AG (CH) 2014-01-03 WO disclosed
WO-2014002057-A1 PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS NOVARTIS AG (CH) 2014-01-03 WO disclosed
US-20120295884-A1 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2012-11-22 US disclosed
US-20120295884-A1 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2012-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150141455-A1 COMPLEMENT PATHWAY MODULATORS AND USES THEREOF C5, C3AR1, C9 AGTR2 279/4885MEN1 493/4885KMT2A 4679/4885
US-20120295884-A1 Complement pathway modulators and uses thereof C5, C3AR1, C9 AGTR2 323/4885MEN1 443/4885KMT2A 4723/4885
US-20150191462-A1 PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS C5, TFPI, C9 AGTR2 629/4885MEN1 1661/4885KMT2A 4698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.